Form 4: 4D Molecular Therapeutics Chief Legal Officer Reports Stock Transactions

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.

Summary

• On July 11, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, executed transactions involving the company's stock.
• Bizily exercised stock options to acquire 1,996 shares at a price of $15.78 per share.
• Simultaneously, Bizily sold 1,996 shares at $25 per share.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on October 10, 2023.
• Following these transactions, Bizily directly owns 6,781 shares of common stock.
• Bizily also owns 23,004 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information. The sale could be for personal diversification or liquidity needs.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates